A real-world approach to insulin therapy in primary care practice

Clinical Diabetes

Volumn 23, Issue 2, 2005, Pages 78-86

  Hirsch, Irl B ^a   Bergenstal, Richard M ^b,c   Parkin, Christopher G ^d   Wright Jr , Eugene ^e   Buse, John B ^f,g  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b INTERNATIONAL DIABETES CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d CGParkin Communications Inc   (United States)

^e Primary Care and Specialty Practices of Cape Fear Valley Health System   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g Diabetes Care Center

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL PROTOCOL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; TITRIMETRY; TREATMENT OUTCOME;

EID: 22044434979     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.23.2.78     Document Type: Review

References (47)

1. Maedler K, Donath MY: Cells in type 2 diabetes: a loss of function and mass. Horm Res 62 (Suppl. 3):67-73, 2004
2. Wallace TM, Matthews DR: Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. Q J Med 93:369-374, 2000
3. Brown JB, Nichols GA: Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care 9:213-217, 2003
4. Roach P, Koledova E, Metcalfe S, Hultman C, Milicevic Z, the Romania/Russia Mix25 Study Group: Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther 23:1732-1744, 2001
5. Niskanen L, Jensen LE, Rastam J, Nygaard-Pedersen L, Erichsen K, Vora JP: Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 26:531-540, 2004
6. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
7. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 16:21-31, 1993
8. Writing Team for the DCCT/EDIC Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
9. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, Piconi L, Assaloni R, Motz E: The postprandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 21:171-175, 2004
10. Esposito K, Giugliano D, Nappo F, Marfella R, the Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219, 2004
11. Rosenstock J, Samols E, Muchmore DB, Schneider J: Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 19:1194-1199, 1996
12. Blaum CS, Velez L, Hiss RG, Halter JB: Characteristics related to poor glycemic control in NIDDM patients in community practice. Diabetes Care 20:7-11, 1997
13. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
14. Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 99:2626-2632, 1999
15. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001
16. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 67:352-360, [discussion 360-362], 1999
17. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS: Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 109:1497-1502, 2004
18. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S: Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 37:41-46, 2000
19. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 157:1249-1255, 1997
20. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631-636, 2001
21. Jacobon L, Sogaard B, Riis A: Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 56:399-403, 2000
22. Roach P, Trautmann ME, Anderson JH, the Mix25 Study Group: Improved postprandial glycemia during treatment with an intermediateacting insulin mixture, Mix25 (Abstract). Diabetologia 41 (Suppl. 1):A244, 1998
23. Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr, and the Mix50 Study Group: Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Clin Ther 21:523-534, 1999
24. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation effects of short- and long-term simvastatin treatment. Circulation 106:1211-1218, 2002
25. 1c level. Diabetes Care 23:1830-1834, 2000
26. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T: Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144:229-235, 1999
27. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050-1054, 1999
28. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged non-diabetic men. Diabetes Care 21:360-367, 1998
29. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
30. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012, 1999
31. Groop LC: Sulfonylureas in NIDDM. Diabetes Care 15:737-754, 1992
32. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
33. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
34. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S: Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 278:1663-1669, 1997
35. UKPDS Study Group: UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 21:87-92, 1998
36. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 28 (Suppl. 1):S4-S36, 2005
37. 37American Association of Clinical Endocrinologists: Medical guidelines for the management of diabetes mellitus. Endocr Pract 8 (Suppl.1):40-82, 2002
38. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P: Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 26:2238-2243, 2003
39. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, for the Lispro Mixture-Glargine Study Group: Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16 week, randomized, open label, cross-over study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 26:2034-2044, 2004
40. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B: Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005. In press
41. Raskin P, Rojas P, Allen E: Comparison of twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) with once-daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabetic agents. Diabetes 53 (Suppl. 2):602-P, 2004
42. Mayfield JA, White RD: Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 70:489-500, 2004
43. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562-568, 1999
44. Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine 4002 Study Investigators: The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086, 2003
45. Hirsch IB: Blood glucose monitoring technology: translating data into practice. Endocr Pract 10:67-76, 2004
46. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 27:17-20, 2004
47. 1c. Diabetes Care 26:881-885, 2003